Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Novici Biotech LLC
- Proposal award date
- 2016-08-15
- Contract end date
- 2019-05-31
- UEI
- MQ8XBWAV5826
- Solicitation number
- PA14-072
- Topic code
- NHLBI
Research abstract
DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year It is estimated that the number of deaths due to fibrosis is double the number of
deaths due to cancer and that organ fibrosis results in significant physical emotional and financial burdens Specifically lung fibrosis can be idiopathic associated with connective tissue
diseases or triggered by environmental and occupational exposures such as radiotherapy There are currently no effective therapies to treat existing lung fibrosis and the only option for
patients is organ transplantation We have identified a peptide derived from endostatin now called Endopep which exerts anti fibrotic effects in vitro ex vivo and in vivo in pre clinical models of lung fibrosis Endopep was effective whether administered concomitantly with the fibrotic trigger or days after the trigger and appears to reverse fibrosis an effect not seen wit other drugs being evaluated for these illnesses We propose to produce recombinant Endopep by transient expression in whole plants and test the efficacy of the plant made product in our in vitro ex vivo and in vivo pre clinical models of fibrosis We also propose to conduct pharmacokinetic pharmacodynamic biodistribution and early toxicity studies in preparation for an IND application We have assembled a unique team with the expertise to express the peptide in plants conduct the pre clinical testing and complete the early PK PD biodistribution and toxicity studies in order to translate our findings to the clinic PUBLIC HEALTH RELEVANCE Pulmonary fibrosis is a terminal complication of diseases such as idiopathic pulmonary fibrosis IPF and systemic sclerosis SSc We have identified a novel peptide with anti fibrotic activity that is effective at blocking and reversing lung fibrosis We propose to manufacture the peptide in plants test the plant made product for efficacy in our pre clinical models and conduct pharmacokinetic biodistribution and early toxicity studies in preparation for IND application filing
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
2 SBIR/STTR records share this UEI (2015–2016). Reported award amounts total $1,692,846. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards